These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
615 related articles for article (PubMed ID: 7636254)
1. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. Meluleni GJ; Grout M; Evans DJ; Pier GB J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254 [TBL] [Abstract][Full Text] [Related]
2. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Pier GB Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760 [TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
4. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins. Pier GB; Grout M; Desjardins D J Immunol; 1991 Sep; 147(6):1869-76. PubMed ID: 1832427 [TBL] [Abstract][Full Text] [Related]
5. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. Pier GB; Saunders JM; Ames P; Edwards MS; Auerbach H; Goldfarb J; Speert DP; Hurwitch S N Engl J Med; 1987 Sep; 317(13):793-8. PubMed ID: 2957591 [TBL] [Abstract][Full Text] [Related]
6. Opsonization of mucoid and non-mucoid Pseudomonas aeruginosa by serum from patients with cystic fibrosis assessed by a chemiluminescence assay. LeBlanc CM; Bortolussi R; Issekutz AC; Gillespie T Clin Invest Med; 1982; 5(2-3):125-8. PubMed ID: 6811181 [TBL] [Abstract][Full Text] [Related]
7. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses. Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330 [TBL] [Abstract][Full Text] [Related]
8. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa. Pier GB; Takeda S; Grout M; Markham RB J Clin Invest; 1993 Mar; 91(3):1079-87. PubMed ID: 8450038 [TBL] [Abstract][Full Text] [Related]
9. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. Pedersen SS APMIS Suppl; 1992; 28():1-79. PubMed ID: 1449848 [TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571 [TBL] [Abstract][Full Text] [Related]
13. Nonspecific immunoglobulin synthesis and elevated IgG levels in rabbits immunized with mucoid exopolysaccharide from cystic fibrosis isolates of Pseudomonas aeruginosa. Pier GB; Elcock ME J Immunol; 1984 Aug; 133(2):734-9. PubMed ID: 6234359 [TBL] [Abstract][Full Text] [Related]
14. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Pier GB; Coleman F; Grout M; Franklin M; Ohman DE Infect Immun; 2001 Mar; 69(3):1895-901. PubMed ID: 11179370 [TBL] [Abstract][Full Text] [Related]
15. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. Kronborg G APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034 [TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072 [TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases. Holby N; Olling S Acta Pathol Microbiol Scand C; 1977 Apr; 85(2):107-14. PubMed ID: 404841 [TBL] [Abstract][Full Text] [Related]
18. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Stiver HG; Zachidniak K; Speert DP Clin Invest Med; 1988 Aug; 11(4):247-52. PubMed ID: 2971496 [TBL] [Abstract][Full Text] [Related]
20. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Pier GB; DesJardin D; Grout M; Garner C; Bennett SE; Pekoe G; Fuller SA; Thornton MO; Harkonen WS; Miller HC Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]